Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats

Basit Öğe Kaydı
dc.authoridOZYURT, Huseyin/0000-0003-2327-4082
dc.authoridArmutcu, Ferah/0000-0002-3218-9480
dc.authoridKaplan, Suleyman/0000-0003-1477-5002
dc.authorwosidOZYURT, Huseyin/N-4351-2015
dc.authorwosidArmutcu, Ferah/A-1364-2019
dc.authorwosidKaplan, Suleyman/A-5396-2008
dc.contributor.authorSogut, S
dc.contributor.authorOzyurt, H
dc.contributor.authorArmutcu, F
dc.contributor.authorKart, L
dc.contributor.authorIraz, M
dc.contributor.authorAkyol, O
dc.contributor.authorOzen, S
dc.date.accessioned2024-08-04T20:15:11Z
dc.date.available2024-08-04T20:15:11Z
dc.date.issued2004
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOxidative stress plays an important role in the pathogenesis of idiopathic pulmonary fibrosis. Therefore, erdosteine, an antioxidant, is expected to have an inhibitor potential against the disease. Rats were given one dose of bleomycin in pulmonary fibrosis groups and saline in controls. The first dose of oral erdosteine (10 mg/kg/day) was given 2 days before the bleomycin injection to achieve the plateau level in blood and continued until killing. At day 14, fibrotic changes were evaluated, using Aschoft's criteria and lung hydroxyproline content. Bleomycin produced a fivefold increase in fibrosis score that was decreased by 87% by erdosteine (P>0.001) and almost twofold increases in hydroxyproline content which were completely prevented by erdosteine. Myeloperoxidase activities and MDA levels, which were significantly higher in the bleomycin group, were then significantly attenuated by erdosteine. These results revealed that oral erdosteine may prevent the development of acute pulmonary inflammation caused by bleomycin injection via the repression of neutrophil accumulation and lipid peroxidation, resulting in the inhibition of subsequent lung fibrosis. (C) 2004 Elsevier B.V. All rights reserved.en_US
dc.identifier.doi10.1016/j.ejphar.2004.04.045
dc.identifier.endpage220en_US
dc.identifier.issn0014-2999
dc.identifier.issn1879-0712
dc.identifier.issue2-3en_US
dc.identifier.pmid15212977en_US
dc.identifier.scopus2-s2.0-2942722440en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage213en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejphar.2004.04.045
dc.identifier.urihttps://hdl.handle.net/11616/94201
dc.identifier.volume494en_US
dc.identifier.wosWOS:000222398600017en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofEuropean Journal of Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjecterdosteineen_US
dc.subjectbleomycinen_US
dc.subjectlung fibrosisen_US
dc.subjectmyeloperoxidaseen_US
dc.subjecthydroxyprolineen_US
dc.titleErdosteine prevents bleomycin-induced pulmonary fibrosis in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu